Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Systematic Review Article

Effects of Diacerein Intake on Cardiometabolic Profiles in Type 2 Diabetics: A Systematic Review and Meta-Analysis of Clinical Trials

Author(s): Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Mohammad Jalali, Navid Jamali, Shahla Rezaei, Kamran Hessami, Pedram Keshavarz, Saeed Shahabi, Ali-Asghar Kolahi, Kristin Carson‐Chahhoud, Amirhossein Sahebkar and Saeid Safiri*

Volume 28, Issue 4, 2021

Published on: 28 July, 2020

Page: [840 - 852] Pages: 13

DOI: 10.2174/0929867327666200728134755

Price: $65


Background: A systematic review and meta-analysis of clinical trials were undertaken to evaluate the effect of diacerein intake on cardiometabolic profiles in patients with type 2 diabetes mellitus (T2DM).

Methods: Electronic databases such as PubMed, EMBASE, Scopus, Web of Science, Google Scholar, and Cochrane Central Register of Controlled Trials were searched from inception to 31 July 2019. Statistical heterogeneity was evaluated using Cochran’s Q test and I-square (I2) statistic. Data were pooled using random-effects models and weighted mean difference (WMD).

Results: From 1,733 citations, seven clinical trials were eligible for inclusion and meta-analysis. A significant reduction in hemoglobin A1c (HbA1c) (WMD -0.73; 95%CI -1.25 to -0.21; P= 0.006; I2= 72.2%) and body mass index (BMI) (WMD -0.55; 95%CI -1.03 to -0.07; P= 0.026; I2= 9.5%) was identified. However, no significant effect of diacerein intake was identified on fasting blood sugar (FBS) (WMD -9.00; 95%CI -22.57 to 4.57; P= 0.194; I2= 60.5%), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD 0.39; 95%CI -0.95 to 1.73; P= 0.569; I2= 2.2%), body weight (WMD - 0.54; 95%CI -1.10 to 0.02; P= 0.059), triglycerides (WMD -0.56; 95%CI -24.16 to 23.03; P= 0.963; I2= 0.0%), total-cholesterol (WMD -0.21; 95%CI -12.19 to 11.78; P= 0.973; I2= 0.0%), HDL-cholesterol (WMD -0.96; 95%CI -2.85 to 0.93; P= 0.321; I2= 0.0%), and LDL-cholesterol levels (WMD -0.09; 95%CI -8.43 to 8.25; P= 0.983; I2= 37.8%).

Conclusion: Diacerein intake may reduce HbA1c and BMI; however, no evidence of the effect was observed for FBS, HOMA-IR, body weight, triglycerides, total cholesterol, HDL-cholesterol or LDLcholesterol.

Keywords: Diacerein, diabetes mellitus, cardiometabolic, Meta-analysis, body weight, triglycerides.

« Previous
Hamoudi, R.; Saheb Sharif-Askari, N.; Saheb Sharif-Askari, F.; Abusnana, S.; Aljaibeji, H.; Taneera, J.; Sulaiman, N. Prediabetes and diabetes prevalence and risk factors comparison between ethnic groups in the United Arab Emirates. Sci. Rep., 2019, 9(1), 17437.
[] [PMID: 31767874]
IDF Diabetes Atlas, Brussels: International Diabetes Federation, 8th Edition; , 2017.
Lourenço, C.; Kelly, D.; Cantillon, J.; Cauchi, M.; Yon, M.A.; Bentley, L.; Cox, R.D.; Turner, C. Monitoring type 2 diabetes from volatile faecal metabolome in Cushing’s syndrome and single Afmid mouse models via a longitudinal study. Sci. Rep., 2019, 9(1), 18779.
[] [PMID: 31827172]
Classification of diabetes mellitus. Geneva:; World Health Organization, 2019.
Saydah, S.H.; Siegel, K.R.; Imperatore, G.; Mercado, C.; Gregg, E.W. The cardiometabolic risk profile of young adults with diabetes in the US. Diabetes Care, 2019, 42(10), 1895-1902.
[] [PMID: 31221678]
Louthrenoo, W.; Nilganuwong, S.; Nanagara, R.; Siripaitoon, B.; Collaud Basset, S. Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial. Clin. Rheumatol., 2019, 38(9), 2461-2471.
[] [PMID: 31104217]
Malaguti, C.; Vilella, C.A.; Vieira, K.P.; Souza, G.H.; Hyslop, S. Zollner, Rde.L. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in non-obese diabetic (NOD) mice. Int. Immunopharmacol., 2008, 8(6), 782-791.
[] [PMID: 18442781]
Tres, G.S.; Fuchs, S.C.; Piovesan, F.; Koehler-Santos, P.; Pereira, F.D.S.; Camey, S.; Lisboa, H.K.; Moreira, L.B. Effect of diacerein on metabolic control and inflammatory markers in patients with type 2 diabetes using antidiabetic agents: a randomized controlled trial. J. Diabetes Res., 2018, 20184246521
[] [PMID: 29805981]
Piovesan, F.; Tres, G.S.; Moreira, L.B.; Andrades, M.E.; Lisboa, H.K.; Fuchs, S.C. Effect of diacerein in renal function, metabolic control, and inflammatory markers in type 2 diabetic patients with nephropathy. PLoS One, 2013, 12(10)e0186554
[ ] [PMID: 29049415]
Piovesan, F.; Tres, G.S.; Moreira, L.B.; Andrades, M.E.; Lisboa, H.K.; Fuchs, S.C. Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: a randomized controlled trial. PLoS One, 2017, 12(10)e0186554
[] [PMID: 29049415]
Ramos-Zavala, M.G.; González-Ortiz, M.; Martínez-Abundis, E.; Robles-Cervantes, J.A.; González-López, R.; Santiago-Hernández, N.J. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care, 2011, 34(7), 1591-1594.
[] [PMID: 21610123]
Cardoso, C.R.L.; Leite, N.C.; Carlos, F.O.; Loureiro, A.A.; Viegas, B.B.; Salles, G.F. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Care, 2017, 40(10), 1356-1363.
[] [PMID: 28818994]
Villar, M.M.; Martínez-Abundis, E.; Preciado-Márquez, R.O.; González-Ortiz, M. Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch. Endocrinol. Metab., 2017, 61(2), 188-192.
[] [PMID: 28225996]
Guyatt, G.H.; Oxman, A.D.; Vist, G.E.; Kunz, R.; Falck-Ytter, Y.; Alonso-Coello, P.; Schünemann, H.J. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650), 924-926.
[] [PMID: 18436948]
Joo, N-S.; Kim, S-M.; Kim, K-M.; Kim, C-W.; Kim, B-T.; Lee, D-J. Changes of body weight and inflammatory markers after 12-Week intervention trial: results of a double-blind, placebo-control pilot study. Random. Control. Trial, 2011, 52(2), 242-248.
[] [PMID: 21319341]
Leite, N.C.; Viegas, B.B.; Villela-Nogueira, C.A.; Carlos, F.O.; Cardoso, C.R.L.; Salles, G.F. Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized, placebo-controlled trial. Diabetes Obes. Metab., 2019, 21(5), 1266-1270.
[] [PMID: 30687994]
Zhang, Q.; Zhou, J.; Wang, Y.; Chen, D. The effect and safety of diacerein in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Am. J. Clin. Exp. Immunol., 2017, 6(6), 97-106.
[PMID: 29348985]
Liu, S.; Hempe, J.M.; McCarter, R.J.; Li, S.; Fonseca, V.A. Association between inflammation and biological variation in hemoglobin A1c in U.S. nondiabetic adults. J. Clin. Endocrinol. Metab., 2015, 100(6), 2364-2371.
[] [PMID: 25867810]
Wu, T.; Dorn, J.P.; Donahue, R.P.; Sempos, C.T.; Trevisan, M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the third national health and nutrition examination survey, 1988-1994. Am. J. Epidemiol., 2002, 155(1), 65-71.
[] [PMID: 11772786]
Brown, C.O. A dose-ranging study of diacerein in patients with type 2 diabetes. In: Amer Diabetes Assoc 1701 N Beauregard ST, Alexandria, VA 22311-1717 USA, 2013.
Tobar, N.; Oliveira, A.G.; Guadagnini, D.; Bagarolli, R.A.; Rocha, G.Z.; Araújo, T.G.; Santos-Silva, J.C.; Zollner, R.L.; Boechat, L.H.; Carvalheira, J.B.; Prada, P.O.; Saad, M.J. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology, 2011, 152(11), 4080-4093.
[] [PMID: 21896669]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy